113,600 research outputs found
Pläne und Ansichten / 31 Description exacte et fidele des villes, bourgs et villages qui les ambassadeurs de Hollande ont rencontrez dans leur voyages par terre de la ville d'Osacca jusqu'a Iedo capitale du Japon : ; Voyage des ambassadeurs de Hollande par mer, de Nangasacqui à Osacca
No full textexactement decrit, presentement publiée par P. van der Aa, marchand libraireOben: "Description exacte ...", unten: "Voyage des ambassadeurs ..."Titelkartusche und Massstabsleisten jeweils unten recht
Ryhiner-Kartensammlung / 49 Description exacte et fidele des villes, bourgs et villages qui les ambassadeurs de Hollande ont rencontrez dans leur voyages par terre de la ville d'Osacca jusqu'a Iedo capitale du Japon : ; Voyage des ambassadeurs de Hollande par mer de Nangasacqui à Osacca
No full textexactement decrit ; presentement publiée par P. van der Aa, marchand libraireTitelkartusche und Massstabsleisten jeweils unten rechtsOben: "Description exacte ...", unten: "Voyage des ambassadeurs ...
Eprodisate for the treatment of renal disease in AA amyloidosis
No full textBackground: Amyloid A (AA) amyloidosis is a complication of chronic inflammatory conditions that develops when proteolytic fragments of serum amyloid A protein (SAA) are deposited in tissues as amyloid fibrils. Amyloid deposition in the kidney causes progressive deterioration in renal function. Eprodisate is a member of a new class of compounds designed to interfere with interactions between amyloidogenic proteins and glycosaminoglycans and thereby inhibit polymerization of amyloid fibrils and deposition of the fibrils in tissues.
Methods: We performed a multicenter, randomized, double-blind, placebo-controlled trial to evaluate the efficacy and safety of eprodisate in patients with AA amyloidosis and kidney involvement. We randomly assigned 183 patients from 27 centers to receive eprodisate or placebo for 24 months. The primary composite end point was an assessment of renal function or death. Disease was classified as worsened if any one of the following occurred: doubling of the serum creatinine level, reduction in creatinine clearance by 50% or more, progression to end-stage renal disease, or death.
Results: At 24 months, disease was worsened in 24 of 89 patients who received eprodisate (27%) and 38 of 94 patients given placebo (40%, P=0.06); the hazard ratio for worsening disease with eprodisate treatment was 0.58 (95% confidence interval, 0.37 to 0.93; P=0.02). The mean rates of decline in creatinine clearance were 10.9 and 15.6 ml per minute per 1.73 m2 of body-surface area per year in the eprodisate and the placebo groups, respectively (P=0.02). The drug had no significant effect on progression to end-stage renal disease (hazard ratio, 0.54; P=0.20) or risk of death (hazard ratio, 0.95; P=0.94). The incidence of adverse events was similar in the two groups.
Conclusions: Eprodisate slows the decline of renal function in AA amyloidosis
Natural history and outcome in systemic AA amyloidosis
No full textBACKGROUND:Deposition of amyloid fibrils derived from circulating acute-phase reactant serum amyloid A protein (SAA) causes systemic AA amyloidosis, a serious complication of many chronic inflammatory disorders. Little is known about the natural history of AA amyloidosis or its response to treatment.METHODS:We evaluated clinical features, organ function, and survival among 374 patients with AA amyloidosis who were followed for a median of 86 months. The SAA concentration was measured serially, and the amyloid burden was estimated with the use of whole-body serum amyloid P component scintigraphy. Therapy for inflammatory diseases was administered to suppress the production of SAA.RESULTS:Median survival after diagnosis was 133 months; renal dysfunction was the predominant disease manifestation. Mortality, amyloid burden, and renal prognosis all significantly correlated with the SAA concentration during follow-up. The risk of death was 17.7 times as high among patients with SAA concentrations in the highest eighth, or octile, (greater/equal 155 mg per liter) as among those with concentrations in the lowest octile (< 4 mg per liter); and the risk of death was four times as high in the next-to-lowest octile (4 to 9 mg per liter). The median SAA concentration during follow-up was 6 mg per liter in patients in whom renal function improved and 28 mg per liter in those in whom it deteriorated (P < 0.001). Amyloid deposits regressed in 60% of patients who had a median SAA concentration of less than 10 mg per liter, and survival among these patients was superior to survival among those in whom amyloid deposits did not regress (P=0.04).CONCLUSIONS:The effects of renal dysfunction dominate the course of AA amyloidosis, which is associated with a relatively favorable outcome in patients with SAA concentrations that remain in the low-normal range (< 4 mg per liter)
Les Indes Orientales suivant les nouvelles observations de Messrs. de l'Academie Royale des Sciences etc. augmentées de nouveau [cartographic material]
No full textMap of Southeast Asia and India showing part of northern Australia as Nova Hollandia with relief shown pictorially.; "Avec privilege".; Plate 1 from: La galerie agr'eable du monde / Pieter vander Aa. Leide : Pierre vander Aa, [1729?]; NUC, pre 1956, v. 1, p. 99.; Also available in an electronic version via the Internet at: http://nla.gov.au/nla.map-rm294
Ryhiner-Kartensammlung / 14 Morée, autrefois le Peloponnese : avec toutes ses iles
No full textdressée par les plus exactes géographes et nouvellement publiée par Pierre vander Aa, marchand libraire à LeideTitel- und Massstabskartusche unten link
L'Asie [cartographic material] : selon les nouvelles observations de Messrs. de l'Academie des Sciences, etc.
No full textMap of Asia showing Europe, Saudi Arabia, India, Japan and Southeast Asia. Relief shown pictorially.; Insets: Kaimachitae. Scale [ca. 1:6,336,000?] -- Provincia Leaotunia. Scale [ca. 1: 6,336,000?].; Title from decorative cartouche.; At head of map: Asia in praecipuas ipsius partes distributa, ad observationes academiae regiae scientiarum, et exquisitissimas tabulas, quae nunquam antehac lucem viderunt , excusa a Petro vander Aa, cum privilegio ordinum Hollandiae et westfrisiae.; Map imprint: A Leide : Chez Pierre vander Aa. avec privilege.; From: Le nouveau théâtre du monde / Pieter van der Aa. A Leide: Chez Pierre vander Aa, Marchand Libraire, 1713.; NUC, pre 1956, v.1, p. 100.; Also available in an electronic version via the Internet at: http://nla.gov.au/nla.map-rm160.Asia in praecipuas ipsius parte
Renal AA-amyloidosis in intravenous drug users - a role for HIV-infection?
No full textBackground: Chronic renal disease is a serious complication of long-term intravenous drug use (IVDU). Recent reports have postulated a changing pattern of underlying nephropathy over the last decades.
Methods: Retrospective investigation including all patients with prior or present IVDU that underwent renal biopsy because of chronic kidney disease between 01.04.2002 and 31.03.2012 in the city of Frankfurt/Main, Germany.
Results: Twenty four patients with IVDU underwent renal biopsy because of progressive chronic kidney disease or proteinuria. Renal AA-amyloidosis was the predominant cause of renal failure in 50% of patients. Membranoproliferative glomerulonephritis (GN) was the second most common cause found in 21%. Patients with AA-amyloidosis were more likely to be HIV infected (67 vs.17%; p=0.036) and tended to have a higher rate of repeated systemic infections (92 vs. 50%; p=0.069). Patients with AA-amyloidosis presented with progressive renal disease and nephrotic-range proteinuria but most patients had no peripheral edema or systemic hypertension. Development of proteinuria preceded the decline of GFR for approximately 1--2 years.
Conclusions: AA-amyloidosis was the predominant cause of progressive renal disease in the last 10 years in patients with IVDU. The highest rate of AA-amyloidosis observed was seen in HIV infected patients with IVDU. We speculate that chronic HIV-infection as well as the associated immunosuppression might promote development of AA-amyloidosis by increasing frequency and duration of infections acquired by IVDU
- …
